Table 2 Baseline demographics and patient characteristics overall and by cohort
Characteristic | Dose escalation cohort (n = 13) | Expansion cohort (n = 50) | Overall (n = 63) |
|---|---|---|---|
Age, year | |||
 Mean | 58.1 | 57.7 | 57.8 |
 Median | 55.1 | 57.2 | 57.2 |
 Range | 40.7–80.7 | 35.8–75.5 | 35.8–80.7 |
Gender, n (%) | |||
 Male | 7 (54) | 30 (60) | 37 (59) |
 Female | 6 (46) | 20 (40) | 26 (41) |
Race | |||
 White | 11 (85) | 29 (58) | 40 (63) |
 Black | 2 (15) | 14 (28) | 16 (25) |
 Other / unknown | 0 | 7 (14) | 7 (11) |
Performance status, KPS (%) | |||
 100 | 1 (8) | 5 (10) | 6 (9) |
 90 | 7 (54) | 18 (36) | 25 (40) |
 80 | 3 (23) | 24 (48) | 27 (43) |
 70 | 2 (15) | 3 (6) | 5 (8) |
# of prior treatments (%) | |||
 1 | 1 (8) | 2 (4) | 3 (5) |
 2 | 5 (38) | 10 (20) | 15 (24) |
 3 | 6 (46) | 17 (34) | 23 (31) |
 4 | 0 | 12 (24) | 12 (19) |
  ≥ 5 | 1 (8) | 9 (18) | 10 (16) |
Tumor Type, n (%) | |||
 Breast | 4 (31) | 0 | 4 (6) |
 Colon | 5 (38) | 41 (82) | 46 (73) |
 Esophagus | 1 (8) | 0 | 1 (2) |
 Gastric | 2 (15) | 0 | 2 (3) |
 GI | 1 (8) | 0 | 1 (2) |
 Rectum | 0 | 9 (18) | 9 (14) |